{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:06:40Z","timestamp":1792786000804,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Open Societal Challenges Programme"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Late-stage prostate cancer is treated with hormonal therapy. While initially effective, development of drug resistance is common. Hypoxia, a local-environmental occurrence in tumours, is known to trigger hormone-independence and concurrent drug resistance in cancer cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here we analyse single-cell transcriptomes of LNCaP cells throughout drug treatment. These cells were exposed to chronic hypoxia and treated with Enzalutamide, a hormonal drug which inhibits the androgen receptor, both with and without Tazemetostat, an epigenetic drug that inhibits EZH2 catalytic activity, which renders Enzalutamide-resistant clones partially sensitive to hormonal therapies. We identify genes characterizing the resistant clone and assess clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We characterize a resistant cluster present with Enzalutamide treatment but not with combination therapy. The top 10 upregulated genes in this cluster included genes previously linked to resistance: DDIT3, MDM2, and CDKN1A, and one previously proposed as a pan-cancer hallmark (HSP90B1). Analysis of clinical databases showed expression of CDKN1A, POLH, and GADD54 to be significantly upregulated in association with neuroendocrine prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This work characterizes at a single-cell level the Enzalutamide resistant clone and the impact of epigenetic inhibitors on resistance development. This characterization may enable the identification of resistant and non-resistant cells by their gene expression profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgaf100","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:28:16Z","timestamp":1759145296000},"source":"Crossref","is-referenced-by-count":2,"title":["Characterizing resistance in prostate cancer at a single cell level with hormonal treatment and epigenetic inhibitors"],"prefix":"10.1093","volume":"78","author":[{"given":"Morgan","family":"Howells","sequence":"first","affiliation":[{"name":"School of Life Health and Chemical Sciences, The Open University , Walton Hall, Kents Hill, Milton Keynes MK7 6AA ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarsini","family":"Gangadharannambiar","sequence":"additional","affiliation":[{"name":"School of Life Health and Chemical Sciences, The Open University , Walton Hall, Kents Hill, Milton Keynes MK7 6AA ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum","family":"McMullen","sequence":"additional","affiliation":[{"name":"School of Life Health and Chemical Sciences, The Open University , Walton Hall, Kents Hill, Milton Keynes MK7 6AA ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Crea","sequence":"additional","affiliation":[{"name":"School of Life Health and Chemical Sciences, The Open University , Walton Hall, Kents Hill, Milton Keynes MK7 6AA ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8170-8806","authenticated-orcid":false,"given":"Wendi","family":"Bacon","sequence":"additional","affiliation":[{"name":"School of Life Health and Chemical Sciences, The Open University , Walton Hall, Kents Hill, Milton Keynes MK7 6AA ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-5746","authenticated-orcid":false,"given":"Colette","family":"Christiansen","sequence":"additional","affiliation":[{"name":"School of Mathematics and Statistics, The Open University , Walton Hall, Kents Hill, Milton Keynes MK7 6AA ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"2026021208124251900_ref1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14737140.2024.2405103","article-title":"Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment","volume":"24","author":"Miller","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026021208124251900_ref2","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.3390\/cancers14194877","article-title":"The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026021208124251900_ref3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.omtn.2023.02.022","article-title":"Enzalutamide-induced signatures revealed by epigenetic plasticity using single-cell multi-omics sequencing in prostate cancer","volume":"31","author":"Fan","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026021208124251900_ref4","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1038\/s41467-018-07411-7","article-title":"Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen\/AR-targeted therapy","volume":"9","author":"Geng","year":"2018","journal-title":"Nat Commun"},{"key":"2026021208124251900_ref5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","article-title":"The roles of EZH2 in cancer and its inhibitors","volume":"40","author":"Liu","year":"2023","journal-title":"Med Oncol"},{"key":"2026021208124251900_ref6","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1038\/s41467-021-26840-5","article-title":"Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression","volume":"12","author":"Bolis","year":"2021","journal-title":"Nat Commun"},{"key":"2026021208124251900_ref7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"2026021208124251900_ref8","doi-asserted-by":"publisher","first-page":"9911","DOI":"10.1074\/jbc.RA119.008152","article-title":"Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer","volume":"294","author":"Bai","year":"2019","journal-title":"J Biol Chem"},{"key":"2026021208124251900_ref9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.6004\/jadpro.2022.13.2.7","article-title":"Tazemetostat: EZH2 inhibitor","volume":"13","author":"Straining","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"2026021208124251900_ref10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026021208124251900_ref11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF00262024","article-title":"The human prostatic carcinoma cell line LNCaP and its derivatives","volume":"17","author":"Steenbrugge","year":"1989","journal-title":"An overview Urol Res"},{"key":"2026021208124251900_ref12","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41388-023-02680-z","article-title":"Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer","volume":"42","author":"Cameron","year":"2023","journal-title":"Oncogene."},{"key":"2026021208124251900_ref13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1158\/0008-5472.CAN-17-1924","article-title":"Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell-cycle-related transcription and attenuated androgen response","volume":"78","author":"Horning","year":"2018","journal-title":"Cancer Res"},{"key":"2026021208124251900_ref32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia (Auckl)"},{"key":"2026021208124251900_ref16","doi-asserted-by":"publisher","first-page":"W83","DOI":"10.1093\/nar\/gkae410","article-title":"The galaxy platform for accessible, reproducible, and collaborative data analyses: 2024 update","volume":"52","author":"The Galaxy Community","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026021208124251900_ref31","doi-asserted-by":"crossref","unstructured":"Goclowski CL, Jakiela J, Collins T \u00a0et\u00a0al. \u00a0Galaxy as a gateway to bioinformatics: multi-Interface galaxy hands-on training suite (MIGHTS) for scRNA-seq. GigaScience \u00a02025;14:2025. 10.1093\/gigascience\/giae107","DOI":"10.1093\/gigascience\/giae107"},{"key":"2026021208124251900_ref17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol"},{"key":"2026021208124251900_ref18","first-page":"2579","article-title":"Visualising data using t-SNE","volume":"9","author":"Maaten","year":"2008","journal-title":"J Mach Learn Res"},{"key":"2026021208124251900_ref19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.21105\/joss.00861","article-title":"UMAP: uniform manifold approximation and projection","volume":"3","author":"Leland","year":"2018","journal-title":"Journal of Open Source Software"},{"key":"2026021208124251900_ref20","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/bioinformatics\/btaa956","article-title":"Evaluating single-cell cluster stability using the Jaccard similarity index","volume":"37","author":"Tang","year":"2021","journal-title":"Bioinformatics."},{"key":"2026021208124251900_ref14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1158\/0008-5472.CAN-13-2921-T","article-title":"High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development","volume":"74","author":"Lin","year":"2014","journal-title":"Cancer Res"},{"key":"2026021208124251900_ref21a","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"key":"2026021208124251900_ref21","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.3390\/ijms25052836","article-title":"Integrated bioinformatics analysis identified ASNS and DDIT3 as the therapeutic target in castrate-resistant prostate cancer","volume":"25","author":"Jung","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026021208124251900_ref22","first-page":"2082","article-title":"Inactivation of the p53 pathway in prostate cancer: impact on tumor progression","volume":"5","author":"Osman","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2026021208124251900_ref23","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/cncr.21261","article-title":"Radiation therapy oncology group MDM2 as a predictor of prostate carcinoma outcome: an analysis of radiation therapy oncology group protocol 8610","volume":"104","author":"Khor","year":"2005","journal-title":"Cancer."},{"key":"2026021208124251900_ref24","first-page":"2033","article-title":"CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma","volume":"63","author":"Kibel","year":"2003","journal-title":"Cancer Res"},{"key":"2026021208124251900_ref26","doi-asserted-by":"publisher","first-page":"778925","DOI":"10.3389\/fonc.2021.778925","article-title":"Early drug discovery and development of novel cancer therapeutics targeting DNA polymerase eta (POLH)","volume":"11","author":"Wilson","year":"2021","journal-title":"Front Oncol"},{"key":"2026021208124251900_ref28","doi-asserted-by":"publisher","first-page":"e5344","DOI":"10.7717\/peerj.5344","article-title":"The expression and clinical significance of GADD45A in breast cancer patients","volume":"6","year":"2018","journal-title":"PeerJ."},{"key":"2026021208124251900_ref29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1742-4682-10-38","article-title":"Tumor necrosis factor receptor superfamily 10B (TNFRSF10B): an insight from structure modeling to virtual screening for designing drug against head and neck cancer","volume":"10","author":"Tahir","year":"2013","journal-title":"Theor Biol Med Model"},{"key":"2026021208124251900_ref30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12943-023-01920-w","article-title":"Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target","volume":"23","author":"Huang","year":"2024","journal-title":"Mol Cancer"},{"key":"2026021208124251900_ref15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.20517\/cdr.2019.25","article-title":"Molecular mechanisms of enzalutamide resistance in prostate cancer","volume":"2","author":"Blatt","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"2026021208124251900_ref27","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0022-5347(05)00651-8","article-title":"The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer","volume":"175","author":"Pelzer","year":"2006","journal-title":"J Urol"},{"key":"2026021208124251900_ref25","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/2\/rgaf100\/65130779\/rgaf100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/2\/rgaf100\/65130779\/rgaf100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:12:52Z","timestamp":1770901972000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/doi\/10.1093\/jpp\/rgaf100\/8313382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgaf100","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,3]]},"article-number":"rgaf100"}}